Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA

Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Jūlı́us Guðmundsson, Jon K. Sigurdsson, Lilja Stefánsdóttir, Bjarni A. Agnarsson, Helgi J. Ísaksson, Ólafur Andri Stefánsson, Sigurjón A. Guðjónsson, Daníel F. Guðbjartsson, Gísli Másson, Michael L. Frigge, Simon Stacey, Patrick Sulem, Gísli H. Halldórsson, Vinicius Tragante, Hilma Hólm, Guðmundur I. Eyjólfsson, Ólöf Sigurðardóttir, Ísleifur Ólafsson, Þorvaldur Jónsson, Eiríkur Jónsson, Rósa B. Barkardóttir, Rafn Hilmarsson, Folkert W. Asselbergs, Guðmundur Geirsson, Unnur Þorsteinsdóttir, Þórunn Rafnar, Guðmar Þorleifsson, Kāri Stefánsson
Formáid: Artigo
Teanga:Béarla
Foilsithe / Cruthaithe: 2018
Rochtain ar líne:https://doi.org/10.1038/s41467-018-06920-9
https://www.nature.com/articles/s41467-018-06920-9.pdf
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
Cur síos
Achoimre:Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from Iceland and the UK. We discovered 23 genome-wide significant variants, located at 14 loci. There is little or no overlap between the BPH/LUTS variants and published prostate cancer risk variants. However, 15 of the variants reported here also associate with serum levels of prostate specific antigen (PSA) (at a Bonferroni corrected P < 0.0022). Furthermore, there is a strong genetic correlation, rg = 0.77 (P = 2.6 × 10-11), between PSA and BPH/LUTS, and one standard deviation increase in a polygenic risk score (PRS) for BPH/LUTS increases PSA levels by 12.9% (P = 1.6×10-55). These results shed a light on the genetic background of BPH/LUTS and its substantial influence on PSA levels.